複雑性皮膚・皮膚構造感染症治療薬の世界市場レポート 2025年

複雑性皮膚・皮膚構造感染症治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年には152億米ドルに成長し、CAGRは9.8％となります。予測期間の成長は、ヘルスケア支出の増加、研究開発活動への投資の増加、新規抗生物質への需要の高まり、抗生物質耐性感染症の発生率の増加、個別化医療への需要の高まりに起因すると考えられます。予測期間中の世界の動向には、創傷ケア製品の進歩、標的抗生物質、デジタルヘルスモニタリング、自然療法・代替療法、世界コラボレーションなどが含まれます。

皮膚疾患の有病率の増加は、今後数年間における複雑性皮膚・皮膚構造感染症（cSSSI）治療薬市場の成長を促進すると予測されます。皮膚疾患は、皮膚の外観、構造、機能に影響を及ぼす病状であり、皮膚、毛髪、爪、関連組織を侵す可能性があります。cSSSI症例における耐性菌の治療には、さまざまな抗生物質が利用されています。したがって、皮膚疾患の発生率の増加は、新たなcSSSI治療薬の承認につながり、認識を高め、複雑な皮膚および皮膚構造感染症の早期診断を促進します。例えば、2023年2月、英国を拠点とするがん研究機関Cancer Research UKは、英国におけるメラノーマ皮膚がん新規症例の年間平均数が、2023-2025年の約20,800症例から2038-2040年には約26,500症例に増加すると予測されると報告しました。これはメラノーマ罹患率が9％上昇し、2038-2040年には人口10万人当たり年間33例に達すると予測されています。このように、皮膚疾患の有病率の増加がcSSSI治療薬市場の拡大に拍車をかけています。

ヘルスケア支出の増加は、今後数年間における複雑性皮膚・皮膚構造感染症（cSSSI）治療薬市場の成長をさらに促進すると予想されます。ヘルスケア支出とは、特定のヘルスケアシステムまたは経済圏内におけるヘルスケアサービス、関連商品、活動に対する一定期間の総支出を指します。医療費の増加は、複雑性皮膚・皮膚構造感染症治療薬にとって重要な要素であり、医療サービスへのアクセスを向上させるだけでなく、cSSSI治療薬の研究開発・流通を支えています。例えば、2022年3月、米国の連邦政府機関であるメディケア＆メディケイドサービスセンターは、2021-2030年国民医療費（NHE）報告書の中で、国民医療費は2021年から2030年にかけて年平均5.1％の割合で増加し、約6兆8,000億米ドルに達すると予測しました。さらに、メディケア支出は年率7.2％、メディケイド支出は同期間に年率5.6％増加すると予測されています。このように、ヘルスケア支出の増加がcSSSI治療薬市場の成長を後押ししています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界複雑性皮膚・皮膚構造感染症治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の複雑性皮膚・皮膚構造感染症治療薬市場：成長率分析
• 世界の複雑性皮膚・皮膚構造感染症治療薬市場の実績：規模と成長, 2019-2024
• 世界の複雑性皮膚・皮膚構造感染症治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界複雑性皮膚・皮膚構造感染症治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の複雑性皮膚・皮膚構造感染症治療薬市場有効成分別、実績と予測, 2019-2024, 2024-2029F, 2034F
• デラフロキサシン
• バンコマイシン
• セフタロリンフォサミル
• リネゾリド
• その他の有効成分
• 世界の複雑性皮膚・皮膚構造感染症治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 話題
• 非経口
• 世界の複雑性皮膚・皮膚構造感染症治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界の複雑性皮膚・皮膚構造感染症治療薬市場デラフロキサシンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• デラフロキサシン経口錠
• デラフロキサシン注射剤
• 世界の複雑性皮膚・皮膚構造感染症治療薬市場バンコマイシンの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• バンコマイシン経口液
• バンコマイシン注射
• 世界の複雑性皮膚・皮膚構造感染症治療薬市場セフタロリンフォサミルのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• セフタロリンフォサミル注射剤
• 世界の複雑性皮膚・皮膚構造感染症治療薬市場リネゾリドの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• リネゾリド経口錠
• リネゾリド注射剤
• 世界の複雑性皮膚・皮膚構造感染症治療薬市場、その他の有効成分の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ダプトマイシン
• チゲサイクリン
• テイコプラニン

第7章 地域別・国別分析

• 世界の複雑性皮膚・皮膚構造感染症治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の複雑性皮膚・皮膚構造感染症治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 複雑性皮膚・皮膚構造感染症治療薬市場：競合情勢
• 複雑性皮膚・皮膚構造感染症治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Merck & Co. Inc.
• AstraZeneca plc
• Abbott Laboratories
• Sanofi SA
• GlaxoSmithKline plc
• Eli Lilly and Company
• Cipla Inc.
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd
• Fresenius Kabi
• Macleods Pharmaceuticals
• Sun Pharmaceutical Industries Limited
• Dr Reddy's Laboratories Ltd
• Lupin Pharmaceuticals

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 複雑性皮膚・皮膚構造感染症治療薬市場2029：新たな機会を提供する国
• 複雑性皮膚・皮膚構造感染症治療薬市場2029：新たな機会を提供するセグメント
• 複雑性皮膚・皮膚構造感染症治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Complicated skin and skin structure infections (cSSSI) medications are a category of drugs designed to address a range of skin and soft tissue infections (SSTIs) affecting not only the skin but also deeper soft tissues like muscles, fascia, and subcutaneous tissues. These infections typically result from bacterial species and require effective management to prevent complications and enhance patient outcomes.

The primary active ingredients found in drugs for complicated skin and skin structure infections include delafloxacin, vancomycin, ceftaroline, fosamil, linezolid, and others. Delafloxacin, for instance, belongs to the fluoroquinolone antibiotic class, and it is employed for the treatment of skin and skin structure infections caused by specific bacteria. These drugs can be administered through various routes, including oral, topical, and parenteral, and they are utilized by a range of end users, such as hospitals, homecare services, specialty clinics, and others.

The complicated skin and skin structure infections drugs market research report is one of a series of new reports from The Business Research Company that provides complicated skin and skin structure infections drugs market statistics, including complicated skin and skin structure infections drugs industry global market size, regional shares, competitors with a complicated skin and skin structure infections drugs market share, detailed complicated skin and skin structure infections drugs market segments, market trends and opportunities and any further data you may need to thrive in the complicated skin and skin structure infections drugs industry. This complicated skin and skin structure infections drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The complicated skin and skin structure infections drugs market size has grown rapidly in recent years. It will grow from $9.51 billion in 2024 to $10.47 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to infectious disease prevalence, increase in hospital-acquired infections, prevalence of complicated skin and skin structure infections, growing demand for effective treatment options, rising disposable incomes.

The complicated skin and skin structure infections drugs market size is expected to see strong growth in the next few years. It will grow to $15.2 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to increasing healthcare expenditure, increasing investment in r&d activities, rising demand for novel antibiotics, increasing incidence of antibiotic-resistant infections, growing demand for personalized medicine. Major trends in the forecast period include advancements in wound care products, targeted antibiotics, digital health monitoring, natural and alternative remedies, global collaborations.

The increasing prevalence of skin diseases is anticipated to drive the growth of the complicated skin and skin structure infections (cSSSI) drugs market in the coming years. Skin diseases are medical conditions impacting the skin's appearance, structure, and function and may involve the skin, hair, nails, and related tissues. A variety of antibiotic drugs are utilized to treat resistant bacteria in cSSSI cases. Therefore, the rise in skin disease incidence can lead to new cSSSI drug approvals, increase awareness, and promote early diagnosis of complicated skin and skin structure infections. For instance, in February 2023, Cancer Research UK, a UK-based cancer research organization, reported that the average number of new melanoma skin cancer cases each year in the UK is projected to increase from around 20,800 cases in 2023-2025 to approximately 26,500 cases in 2038-2040. This marks a projected 9% rise in melanoma incidence rates, reaching 33 cases per 100,000 people annually by 2038-2040. Thus, the growing prevalence of skin disease is fueling the expansion of the cSSSI drugs market.

Rising healthcare expenditure is expected to further drive the growth of the complicated skin and skin structure infections (cSSSI) drugs market in the coming years. Healthcare expenditure refers to the total spending on healthcare services, related goods, and activities within a specific healthcare system or economy over a given period. Higher healthcare costs are a significant factor for complex skin and skin structure infection medications, not only enhancing access to healthcare services but also supporting the research, development, and distribution of cSSSI medications. For instance, in March 2022, the Centers for Medicare & Medicaid Services, a US-based federal agency, projected in the 2021-2030 National Health Expenditure (NHE) report that national health spending would grow at an average annual rate of 5.1% from 2021 to 2030, reaching nearly $6.8 trillion. Additionally, Medicare spending is anticipated to increase at a 7.2% annual rate, while Medicaid spending is projected to grow by 5.6% annually during the same period. Thus, rising healthcare expenditures are bolstering the growth of the cSSSI drugs market.

To maintain their competitive positions in the complicated skin and skin structure infections drugs market, major companies are committed to developing cutting-edge products. As a case in point, in January 2022, Paladin Labs Inc., a Canadian pharmaceutical company and a subsidiary of Endo International PLC, introduced Xydalba (dalbavancin for injection) in the Canadian market. Xydalba is an intravenous treatment designed for both adults and children aged three months and above, addressing acute bacterial skin and skin structure infections (ABSSSI). This second-generation semi-synthetic lipoglycopeptide antibiotic functions by disrupting the formation of bacterial cell walls, effectively eradicating the bacteria. It demonstrates effectiveness against numerous gram-positive bacteria, including the formidable methicillin-resistant Staphylococcus aureus (MRSA). ABSSSI, denoting Acute Bacterial Skin and Skin Structure Infections, forms a specific subset of complicated skin and skin structure infections (cSSSI).

In March 2022, Cumberland Pharmaceuticals, a pharmaceutical firm based in the United States, joined forces with Tabuk Pharmaceuticals Manufacturing Company to create an innovative antibiotic with life-saving potential for the Middle East. This partnership marked the official launch of Cumberland's Vibativ (telavancin) injection in the Middle East. Vibativ stands as an advanced antibiotic developed to address complicated skin and skin structure infections (cSSIs) attributed to susceptible isolates of gram-positive bacteria. The collaboration entails the exclusive authorization for Tabuk to register and promote the product to patients across Saudi Arabia, Jordan, and potentially other nations in the Middle East. Tabuk Pharmaceuticals Manufacturing Company is a pharmaceutical enterprise headquartered in Saudi Arabia, specializing in the provision of pharmaceutical products within the Middle East and North America.

Major companies operating in the complicated skin and skin structure infections drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Merck & Co. Inc., AstraZeneca PLC, Abbott Laboratories, Sanofi SA, GlaxoSmithKline PLC, Eli Lilly and Company, Cipla Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi, Macleods Pharmaceuticals, Sun Pharmaceutical Industries Limited, Dr Reddy's Laboratories Ltd., Lupin Pharmaceuticals, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, LEO Pharma, Wockhardt, Paratek Pharmaceuticals, Basilea Pharmaceutica AG, Melinta Therapeutics Inc., Nabriva Therapeutics AG, MerLion Pharmaceuticals GmbH.

Asia-Pacific was the largest region in the complicated skin and skin structure infections drugs market in 2024. The regions covered in complicated skin and skin structure infections drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the complicated skin and skin structure infections drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The complicated skin and skin structure infections drugs market consists of sales of pain medications, immunosuppressive medications, antiseptics and wound dressings. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Complicated Skin And Skin Structure Infections Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on complicated skin and skin structure infections drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for complicated skin and skin structure infections drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The complicated skin and skin structure infections drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Active Ingredients: Delafloxacin; Vancomycin; Ceftaroline Fosamil; Linezolid; Other Active Ingredients
• 2) By Route of Administration: Oral; Topical; Parenteral
• 3) By End User: Hospitals; Homecare; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Delafloxacin: Delafloxacin Oral Tablets; Delafloxacin Injectable Form
• 2) By Vancomycin: Vancomycin Oral Solution; Vancomycin Injection
• 3) By Ceftaroline Fosamil: Ceftaroline Fosamil Injection
• 4) By Linezolid: Linezolid Oral Tablets; Linezolid Injectable Form
• 5) By Other Active Ingredients: Daptomycin; Tigecycline; Teicoplanin
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Complicated Skin And Skin Structure Infections Drugs Market Characteristics

3. Complicated Skin And Skin Structure Infections Drugs Market Trends And Strategies

4. Complicated Skin And Skin Structure Infections Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Complicated Skin And Skin Structure Infections Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Complicated Skin And Skin Structure Infections Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Complicated Skin And Skin Structure Infections Drugs Market Growth Rate Analysis
• 5.4. Global Complicated Skin And Skin Structure Infections Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Complicated Skin And Skin Structure Infections Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Complicated Skin And Skin Structure Infections Drugs Total Addressable Market (TAM)

6. Complicated Skin And Skin Structure Infections Drugs Market Segmentation

• 6.1. Global Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Delafloxacin
• Vancomycin
• Ceftaroline Fosamil
• Linezolid
• Other Active Ingredients
• 6.2. Global Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Topical
• Parenteral
• 6.3. Global Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End-Users
• 6.4. Global Complicated Skin And Skin Structure Infections Drugs Market, Sub-Segmentation Of Delafloxacin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Delafloxacin Oral Tablets
• Delafloxacin Injectable Form
• 6.5. Global Complicated Skin And Skin Structure Infections Drugs Market, Sub-Segmentation Of Vancomycin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vancomycin Oral Solution
• Vancomycin Injection
• 6.6. Global Complicated Skin And Skin Structure Infections Drugs Market, Sub-Segmentation Of Ceftaroline Fosamil, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ceftaroline Fosamil Injection
• 6.7. Global Complicated Skin And Skin Structure Infections Drugs Market, Sub-Segmentation Of Linezolid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Linezolid Oral Tablets
• Linezolid Injectable Form
• 6.8. Global Complicated Skin And Skin Structure Infections Drugs Market, Sub-Segmentation Of Other Active Ingredients, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Daptomycin
• Tigecycline
• Teicoplanin

7. Complicated Skin And Skin Structure Infections Drugs Market Regional And Country Analysis

• 7.1. Global Complicated Skin And Skin Structure Infections Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Complicated Skin And Skin Structure Infections Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Complicated Skin And Skin Structure Infections Drugs Market

• 8.1. Asia-Pacific Complicated Skin And Skin Structure Infections Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Complicated Skin And Skin Structure Infections Drugs Market

• 9.1. China Complicated Skin And Skin Structure Infections Drugs Market Overview
• 9.2. China Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Complicated Skin And Skin Structure Infections Drugs Market

• 10.1. India Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Complicated Skin And Skin Structure Infections Drugs Market

• 11.1. Japan Complicated Skin And Skin Structure Infections Drugs Market Overview
• 11.2. Japan Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Complicated Skin And Skin Structure Infections Drugs Market

• 12.1. Australia Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Complicated Skin And Skin Structure Infections Drugs Market

• 13.1. Indonesia Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Complicated Skin And Skin Structure Infections Drugs Market

• 14.1. South Korea Complicated Skin And Skin Structure Infections Drugs Market Overview
• 14.2. South Korea Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Complicated Skin And Skin Structure Infections Drugs Market

• 15.1. Western Europe Complicated Skin And Skin Structure Infections Drugs Market Overview
• 15.2. Western Europe Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Complicated Skin And Skin Structure Infections Drugs Market

• 16.1. UK Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Complicated Skin And Skin Structure Infections Drugs Market

• 17.1. Germany Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Complicated Skin And Skin Structure Infections Drugs Market

• 18.1. France Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Complicated Skin And Skin Structure Infections Drugs Market

• 19.1. Italy Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Complicated Skin And Skin Structure Infections Drugs Market

• 20.1. Spain Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Complicated Skin And Skin Structure Infections Drugs Market

• 21.1. Eastern Europe Complicated Skin And Skin Structure Infections Drugs Market Overview
• 21.2. Eastern Europe Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Complicated Skin And Skin Structure Infections Drugs Market

• 22.1. Russia Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Complicated Skin And Skin Structure Infections Drugs Market

• 23.1. North America Complicated Skin And Skin Structure Infections Drugs Market Overview
• 23.2. North America Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Complicated Skin And Skin Structure Infections Drugs Market

• 24.1. USA Complicated Skin And Skin Structure Infections Drugs Market Overview
• 24.2. USA Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Complicated Skin And Skin Structure Infections Drugs Market

• 25.1. Canada Complicated Skin And Skin Structure Infections Drugs Market Overview
• 25.2. Canada Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Complicated Skin And Skin Structure Infections Drugs Market

• 26.1. South America Complicated Skin And Skin Structure Infections Drugs Market Overview
• 26.2. South America Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Complicated Skin And Skin Structure Infections Drugs Market

• 27.1. Brazil Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Complicated Skin And Skin Structure Infections Drugs Market

• 28.1. Middle East Complicated Skin And Skin Structure Infections Drugs Market Overview
• 28.2. Middle East Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Complicated Skin And Skin Structure Infections Drugs Market

• 29.1. Africa Complicated Skin And Skin Structure Infections Drugs Market Overview
• 29.2. Africa Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Active Ingredients, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Complicated Skin And Skin Structure Infections Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Complicated Skin And Skin Structure Infections Drugs Market Competitive Landscape And Company Profiles

• 30.1. Complicated Skin And Skin Structure Infections Drugs Market Competitive Landscape
• 30.2. Complicated Skin And Skin Structure Infections Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Complicated Skin And Skin Structure Infections Drugs Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Merck & Co. Inc.
• 31.3. AstraZeneca plc
• 31.4. Abbott Laboratories
• 31.5. Sanofi SA
• 31.6. GlaxoSmithKline plc
• 31.7. Eli Lilly and Company
• 31.8. Cipla Inc.
• 31.9. Viatris Inc.
• 31.10. Teva Pharmaceutical Industries Ltd
• 31.11. Fresenius Kabi
• 31.12. Macleods Pharmaceuticals
• 31.13. Sun Pharmaceutical Industries Limited
• 31.14. Dr Reddy's Laboratories Ltd
• 31.15. Lupin Pharmaceuticals

32. Global Complicated Skin And Skin Structure Infections Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Complicated Skin And Skin Structure Infections Drugs Market

34. Recent Developments In The Complicated Skin And Skin Structure Infections Drugs Market

35. Complicated Skin And Skin Structure Infections Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Complicated Skin And Skin Structure Infections Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Complicated Skin And Skin Structure Infections Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Complicated Skin And Skin Structure Infections Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer